Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
This study is ongoing, but not recruiting participants.
Study NCT00043069 Information provided by National Cancer Institute (NCI)
First Received: August 5, 2002 Last Updated: May 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Genital Diseases, Male
Genital Neoplasms, Male
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
calcium carbonate
cholecalciferol
conjugated estrogens
risedronate sodium
Additional drug interventions recognized in this trial
Estrogens
Estrogens, Conjugated (USP)
Risedronic acid
More general drug interventions related to this trial
Antacids
Bone Density Conservation Agents
Calcium Channel Blockers
Cardiovascular Agents
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Membrane Transport Modulators
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamins
Sponsors listed in this trial
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Back to top of Main Content
